Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Blood Pressure|May 31, 2002
Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartanPanagiotis Kotridis, Basile Kokkas, Michalis Karamouzis, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 26, 2021
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in GreeceGeorge Gourzoulidis, Maria Koulentaki, Anna Koumarianou, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility StudyDimitra Galiti, Helena Linardou, Sofia Agelaki, et al.
Biomedicines|May 27, 2023
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal CancerAnna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, et al.
International Journal of Radiation Oncology, Biology, Physics|May 26, 2009
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trialDwight E Heron, Robert L Ferris, Michalis Karamouzis, et al.
Clinical Genitourinary Cancer|October 7, 2015
Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG)Aristotle Bamias, Stavros Peroukidis, Sophia Stamatopoulou, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
ESMO Open|February 22, 2018
Global cancer control: responding to the growing burden, rising costs and inequalities in accessGerald W Prager, Sofia Braga, Branislav Bystricky, et al.
Pageof 2